. Author manuscript; available in PMC: 2016 Feb 29.

Published in final edited form as: Int J Tuberc Lung Dis. 2014 Feb;18(2):147–154. doi: 10.5588/ijtld.13.0627

Table 2a.

Mortality in patients with MDR-TB stratified by the Combined Integrated and Sequential treatment arms and compared to non MDR-TB patients in the SAPiT trial

	MDR-TB patients N =23			All patients both treatment arms N=489

	Combined Integrated treatment arm N=14	Sequential treatment arm N=9	p-value	MDR-TB N=23	non MDR-TB N=466	p-value
Mortality Events	2	5		7	40

Person-years	16.9	8.9		25.8	638.6

Incidence per 100 person-years (95%CI)	11.9 (1.4 – 42.8)	56.0 (18.2 – 130.8)		27.1 (10.9 –55.9)	6.3 (4.5 – 8.5)

	Hazard ratio (95%CI) comparing combined integrated to sequential: 0.14 (0.02 – 0.94) ^§		0.04^§	Incidence rate ratio (95% CI): 0.23 (0.10 – 0.52)^‖		<0.001^‖

^§

adjusted for baseline CD4+ cell count and whether MDR-TB treatment was started

^‖

Proportional hazards regression was not done, because the proportional hazards assumption did not hold. The HR is 0.24 (95% CI: 0.11 to 0.54: P=0.0006), which is similar to the IRR of 0.23.

CI: Confidence interval

MDR-TB: Multidrug resistant tuberculosis